| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Zenas BioPharma, Inc. | Director | Stock Option (Right to Buy) | 18,500 | 10 Jun 2025 | Direct | ||
| ALEXION PHARMACEUTICALS, INC. | EVP, Research & Development | Common Stock, par value $.0001 per share | 0 | $177.00 | 21 Jul 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | 10 Jun 2025 | 1 | $0 | 4 | Director | 12 Jun 2025, 16:32 |
| ZBIO | Zenas BioPharma, Inc. | 12 Sep 2024 | 1 | $0 | 4 | Director | 16 Sep 2024, 21:05 |
| ZBIO | Zenas BioPharma, Inc. | 12 Sep 2024 | 0 | $0 | 3 | Director | 12 Sep 2024, 21:43 |
| /report/000089986621000062-orloff-john-j-2021-07-21 | ALEXION PHARMACEUTICALS, INC. | 21 Jul 2021 | 1 | $0 | 4 | EVP, Research & Development | 23 Jul 2021, 16:29 |
| /report/000089986621000054-orloff-john-j-2021-07-14 | ALEXION PHARMACEUTICALS, INC. | 14 Jul 2021 | 2 | $0 | 4 | EVP, Research & Development | 16 Jul 2021, 16:48 |
| /report/000089986621000050-orloff-john-j-2021-06-08 | ALEXION PHARMACEUTICALS, INC. | 08 Jun 2021 | 1 | -$346,389 | 4 | EVP, Research & Development | 09 Jun 2021, 16:53 |